Traded Nov 26, 2025 · Filed Dec 1, 2025
A board member of Johnson & Johnson spent $258K of their very own money to buy Johnson & Johnson shares. Their pile of Johnson & Johnson shares grew by 209%.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$257,688
Shares × reported transaction price
$100K–$500K
+208.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
43 days after results of Oct 14, 2025, 56 days before results of Jan 21, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $207.56 on Nov 26, 2025, at its 52-week high, after a 9% rise over the previous 30 trading days
52-week range $142.06 (Jan 10, 2025) to $207.56 (Nov 26, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $191.17 on Oct 15, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Darzalex Faspro on Nov 19, 2025, 7 days before this trade.
New use approved (efficacy supplement). Active ingredient: Daratumumab and Hyaluronidase-Fihj. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.7% | +0.2% | -2.9% |
| 30 days | +0.9% | +0.2% | +0.7% |
| 90 days | +21.0% | +0.7% | +20.3% |
| 180 days | +8.8% | +11.3% | -2.5% |
Past results only. Not a forecast.
Congress tradeSits on House Energy and Commerce7 different filers disclosed JNJ within 90 days. Disclosed 29 days after the transaction; reported as an official range, not an exact amount.
8 different filers disclosed JNJ within 90 days. Disclosed 28 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Congress trade